Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Unknown 1Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Conditions

Lymphoma 161Leukemia 99Lymphoma, Large B-Cell, Diffuse 94Precursor Cell Lymphoblastic Leukemia-Lymphoma 92Lymphoma, Non-Hodgkin 91Leukemia, Myeloid, Acute 76Hodgkin Disease 73Lymphoma, Follicular 63Burkitt Lymphoma 60Lymphoma, Mantle-Cell 56Lymphoma, Large-Cell, Immunoblastic 55Small Cell Lung Carcinoma 46Leukemia, Lymphocytic, Chronic, B-Cell 42Lung Neoplasms 41Neuroblastoma 40Lymphoma, B-Cell, Marginal Zone 33Congenital Abnormalities 33Multiple Myeloma 30Recurrence 27Sarcoma 26Central Nervous System Neoplasms 26Carcinoma, Non-Small-Cell Lung 25Myelodysplastic Syndromes 24Leukemia, Myelomonocytic, Acute 24Leukemia, Monocytic, Acute 24Leukemia, Erythroblastic, Acute 24Testicular Neoplasms 22Lymphoma, Large-Cell, Anaplastic 22Leukemia, Megakaryoblastic, Acute 22Brain Neoplasms 22

Interventions

osimertinib 1S 1 (combination) 1Etoposide 1Docetaxel 1Cisplatin 1Bevacizumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Completed × Progression Free Survival × Etoposide × Clear all
NCT03769935 2023-03-29

Maintenance Therapy for Small-cell Lung Cancer

Qingdao Central Hospital

Phase 2 Completed
90 enrolled

Progression Free Survival

Data powered by HemOnc (CC BY 4.0) Colophon âš¡